Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?

Generally speaking in my opinion, concurrent chemoradiation with a platinum drug doublet remains standard of care outside of clinical trials. Definitive chemoradiation in stage III lung cancer is considered a curative regimen despite the risks of local recurrence (around 30%) and distant mets. Bear ...

I completely agree with Dr. @Dr. First Last that the appropriate setting for understanding the interaction between the standard of care for stage III lung cancer (definitive CRT then consolidation IO) and the addition of a novel concurrent agent [IO] to the CRT is in a trial setting. We are currentl...